1. Home
  2. EXEL vs ROKU Comparison

EXEL vs ROKU Comparison

Compare EXEL & ROKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • ROKU
  • Stock Information
  • Founded
  • EXEL 1994
  • ROKU 2002
  • Country
  • EXEL United States
  • ROKU United States
  • Employees
  • EXEL N/A
  • ROKU N/A
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • ROKU Cable & Other Pay Television Services
  • Sector
  • EXEL Health Care
  • ROKU Telecommunications
  • Exchange
  • EXEL Nasdaq
  • ROKU Nasdaq
  • Market Cap
  • EXEL 9.7B
  • ROKU 11.5B
  • IPO Year
  • EXEL 2000
  • ROKU 2017
  • Fundamental
  • Price
  • EXEL $36.20
  • ROKU $75.89
  • Analyst Decision
  • EXEL Buy
  • ROKU Buy
  • Analyst Count
  • EXEL 17
  • ROKU 22
  • Target Price
  • EXEL $35.50
  • ROKU $84.00
  • AVG Volume (30 Days)
  • EXEL 2.5M
  • ROKU 2.6M
  • Earning Date
  • EXEL 02-04-2025
  • ROKU 02-13-2025
  • Dividend Yield
  • EXEL N/A
  • ROKU N/A
  • EPS Growth
  • EXEL 441.02
  • ROKU N/A
  • EPS
  • EXEL 1.55
  • ROKU N/A
  • Revenue
  • EXEL $2,081,598,000.00
  • ROKU $3,896,276,000.00
  • Revenue This Year
  • EXEL $20.53
  • ROKU $18.75
  • Revenue Next Year
  • EXEL $0.95
  • ROKU $13.56
  • P/E Ratio
  • EXEL $23.39
  • ROKU N/A
  • Revenue Growth
  • EXEL 17.31
  • ROKU 15.71
  • 52 Week Low
  • EXEL $20.02
  • ROKU $48.33
  • 52 Week High
  • EXEL $37.59
  • ROKU $99.80
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 58.54
  • ROKU 46.99
  • Support Level
  • EXEL $33.05
  • ROKU $74.92
  • Resistance Level
  • EXEL $37.59
  • ROKU $78.63
  • Average True Range (ATR)
  • EXEL 0.99
  • ROKU 3.46
  • MACD
  • EXEL 0.28
  • ROKU -0.46
  • Stochastic Oscillator
  • EXEL 69.38
  • ROKU 22.22

About EXEL Exelixis Inc.

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About ROKU Roku Inc.

Roku enables consumers to stream television programming. It has more than 80 million streaming households and provided well over 100 billion streaming hours in 2023. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.

Share on Social Networks: